68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy

Global cancer statistics

Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text

Medicine, Oncology, Cancer Epidemiology +15

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

Philip Cornford, Joaquim Bellmunt, M. Bolla et al. · European Urology · 2016 · 1.4K citations

Medicine, Oncology, Urology +17

Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial

Piet Ost, Dries Reynders, Karel Decaestecker et al. · Journal of Clinical Oncology · 2017 · 1.3K citations

Medicine, Oncology, Urology +17

Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy

Matthias Eiber, Tobias Maurer, Michael Souvatzoglou et al. · Journal of Nuclear Medicine · 2015 · 995 citations

Medicine, Nuclear Medicine, Radiology +14

The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

Ali Afshar‐Oromieh, Eleni Avtzi, Frederik L. Giesel et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 974 citations · Full text

Medicine, Nuclear Medicine, Oncology +17